1178670

DE

FORM D

FECENED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL				
OMB NUMBER:	3235-0076			
Expires:	May 30, 2005			
Estimated average burden	•			
hours per response	1.00			

	SEC USE	ONLY	
Prefix		Serial	
	DATE RE	CEIVED	
1	1		

Name of Offering (check if this is an amendment and name has changed, and indicate change.)

Traine of Offering (II check it this is an attending	ent and mane has changed, and more change.)	•	
Series D Convertible Preferred Stock			
Filing Under (Check box(es) that apply):	□ Rule 504 □ Rule 505 ■ Rule 506 □ Section	n 4(6) □ ULOE	
Type of Filing: ■ New Filing □ Amendment			
	A. BASIC IDENTIFICATION DAT	'A	04020517
1. Enter the information requested about the issu	ner		
Name of Issuer (check if this is an amendment	and name has changed, and indicate change.)		
Alnylam Pharmaceuticals, Inc.			
Address of Executive Offices (Number and	Street, City, State, Zip Code)	Telephone Number (Inch	iding Area Code)
790 Memorial Dr., Suite 202, Cambridge, MA	02139	617-252-0700	
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Inclu	oding Area Code)
Brief Description of Business:		······································	
			MAR 23 2004
Type of Business Organization			THOMSON
■ corporation	☐ limited partnership, already formed	□ other (please specify):	FINANCIAL
□ business trust	☐ limited partnership, to be formed	_	***************************************
	Month Year		
Actual or Estimated Date of Incorporation or Org Jurisdiction of Incorporation or Organization: (E	ganization 05 03 ■ Actual □ Estimated nter two-letter U.S. Postal Service abbreviation for State		

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION I

 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Maraganore, John					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Alnylam Pharmaceuticals, Inc., 790	Memorial Dr.,	Suite 202, Cambridge, N	MA 02139		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Greene, Barry					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Alnylam Pharmaceuticals, Inc, 790	Memorial Dr., S	Suite 202, Cambridge, M	IA 02139		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
<u> </u>					
Miles, Vincent J.					
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	le)		
c/o Alnylam Pharmaceuticals, Inc, 790					
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
THE Thomas D					
Ulich, Thomas R. Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)		
Business of Residence Address	(Number and 2	street, city, state, zip co	ie)		
c/o Alnylam Pharmaceuticals, Inc, 790	Memorial Dr., S	Suite 202, Cambridge, M	IA 02139		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
,					
Clarke, John					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
/ 41 1 70 1 1 700		7 1. 000 0 1 11 2	E 1 00100		
c/o Alnylam Pharmaceuticals, Inc, 790					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Barrett, Peter					
Business or Residence Address	(Number and)	Street, City, State, Zip Co	de)	·····	
	(r.camour and	ouver, enty, oute, Esp eo	 0,		
c/o Alnylam Pharmaceuticals, Inc, 790	Memorial Dr., S	Suite 202, Cambridge, N	IA 02139		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Sharp, Phil					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
a/a Alaska Dhamasaatiaala Isaa 700	Managarial Day	Out 4 - 202 - Charle 1 3 N	(4 02120		
c/o Alnylam Pharmaceuticals, Inc, 790 Check Box(es) that Apply:				- D:	
	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Schimmel, Paul					
Business or Residence Address	(Number and	Street, City, State, Zip Co			
business of Residence Fiduress	(ridinoci and	ouce, enj, ouic, mp et	, de j		
c/o Alnylam Pharmaceuticals, Inc, 790	Memorial Dr., S	Suite 202, Cambridge. M	IA 02139		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Westphal, Christoph					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
, , , ,					
c/o Alnylam Pharmaceuticals, Inc, 790	<u>memorial</u> Dr., S	Suite 202, Cambridge, M	IA 02139		

		A. BASIC IDENT	IFICATION DATA		
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and 					
Each general and managing par	tner of partnersh	ip issuers.			
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Berriman, John					
Business or Residence Address	(Number and S	treet, City, State, Zip Co	de)		
c/o Alnylam Pharmaceuticals, Inc, 790 I					
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Starr, Kevin					
Business or Residence Address	(Number and St	reet, City, State, Zip Coo	le)		
ole Abylam Pharmagauticals Inc. 700 l	Mamarial Dr. S	uito 202 Combridge M	TA 82130		
c/o Alnylam Pharmaceuticals, Inc, 790 I Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	LI TOMOLEI	■ Deliencial Owler	L'ACCULIVE OTTICES	Director	U Ocheral allow Wallaging Lattice
(200 1.					
Polaris Venture Partners III, L.P.					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	ode)		
1000 Winter Street, Waltham, MA 024	57				
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Abingworth Bioventures III A, L.P. Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
business of Residence Fiduress	(1 varioes and t	sacci, enj, siaic, zap ec	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		the second second
Princes House, 38 Jermyn Street, Londo	on SWIY 6 DN,	England Attn: Genera	l Counsel		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Abingworth Bioventures III B, L.P.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
n	CHARL C DAI	D 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	10		
Princes House, 38 Jermyn Street, Londo Check Box(es) that Apply:				- n:	
Full Name (Last name first, if individual)	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
run Name (Last name 111st, it morvidual)					
ARCH Venture Fund V, L.P.					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	xde)		
8725 W. Higgins Road, Suite 290, Chica	on II. 60631				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	LI TOMOCI	- Beneficial Owner	B Executive Officer	<u> </u>	Collectar and or retaining 1 across
,					
Atlas Venture Fund VI, L.P.	<u> </u>				
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
890 Winter Street, Suite 320, Waltham,	MA 02451 Att	n: Nina Ross			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
CHP II, L.P. Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)	 -	
Dustriess of Residence Address	(Mumber and)	onwi, Chy, State, Zap Co	AC)		
c/o Cardinal Partners, 221 Nassau Stree	t, Princeton, NJ	08542			

Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: ☐ General and/or Managing Partner □ Promoter ■ Beneficial Owner ☐ Executive Officer □ Director Full Name (Last name first, if individual) Merck & Co., Inc. Business or Residence Address (Number and Street, City, State, Zip Code) One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 Check Box(es) that Apply: ■ Beneficial Owner □ Promoter □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Essential Invest GmbH & Co. KGaA (Number and Street, City, State, Zip Code) Business or Residence Address HRB 1448 Amtsgericht Schwabisch Hall, Germany Check Box(es) that Apply: □ Promoter ■ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Isis Pharmaceuticals, Inc. **Business or Residence Address** (Number and Street, City, State, Zip Code) 2292 Faraday Avenue, Carlsbad, CA 92008-7208 Check Box(es) that Apply: ■ Beneficial Owner □Executive Officer ☐ General and/or Managing Partner □ Promoter □ Director Full Name (Last name first, if individual) Atlas Venture Parallel Fund V **Business or Residence Address** (Number and Street, City, State, Zip Code) 890 Winter Street, Suite 320, Waltham, MA 02451 Attn: Nina Ross Check Box(es) that Apply: ☐ Executive Officer ☐ General and/or Managing Partner □ Promoter □ Beneficial Owner □ Director Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: □ Executive Officer ☐ General and/or Managing Partner □ Promoter □ Beneficial Owner □ Director Full Name (Last name first, if individual) **Business or Residence Address** (Number and Street, City, State, Zip Code) Check Box(es) that Apply: □ Beneficial Owner ☐ Promoter ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) **Business or Residence Address** (Number and Street, City, State, Zip Code) Check Box(es) that Apply: □ Promoter ☐ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) **Business or Residence Address** (Number and Street, City, State, Zip Code)

A. BASIC IDENTIFICATION DATA

B. INFORMATION ABOUT OFFERING						
1	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	Yes	No			
1.	Answer also in Appendix, Column 2, if filing under ULOE.		•			
2.	What is the minimum investment that will be accepted from any individual?	\$ <u>n/a</u>				
		Yes	No			
3.	Does the offering permit joint ownership of a single unit?	•				
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.					
Full none	Name (Last name first, if individual)					
	iness or Residence Address (Number and Street, City, State, Zip Code)	· ·				
200	and of the service (the service and butter, only, same, 22p code)					
Nam	ne of Associated Broker or Dealer	·				
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(Check "All States" or check individual States)	All States				
_ (MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]			
Full	name (Last name first, if individual)	-				
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)	28 184 1, , , , , , , , , , , , , , , , , , ,				
Nam	ne of Associated Broker or Dealer		***************************************			
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(Check "All States" or check individual States)	All States				
_ [MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]			
Full	Name (Last name first, if individual)					
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)					
Nam	ne of Associated Broker or Dealer					
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(Check "All States" or check individual States)	All States				
_ [MT) _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]			

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \Box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>10,000,002</u>	\$ <u>10,000,002</u>
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$ <u>10,000,002</u>	\$ <u>10,000,002</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	1	\$ <u>10,000,002</u>
	Non-accredited Investors	·	\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		φ
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Dollar Amount Sold
	Type of offering	200,	¢
	Rule 505		2
	Regulation A	**	\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	0	\$
	Printing and Engraving Costs		\$
	Legal Fees	•	\$ 20,000
	Accounting Fees	٥	\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	0	\$
	Other Expenses (identify)	0	\$
	Total		\$ 20,000
		=	·

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the \$ 9,980,002 "adjusted gross proceeds to the issuer."..... Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Payments To Officers, Directors, Others & Affiliates Salaries and fees..... Purchase of real estate.... a П Purchase, rental or leasing and installation of machinery and equipment..... Construction or leasing of plant buildings and facilities...... П Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger).... D Repayment of indebtedness..... \Box Working capital.... \$ 9,980,002 Other (specify): _ \Box п \$ 9,980,002 Column Totals..... Total Payments Listed (column totals added) \$ 9,980,002 D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes Date

an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) Signature Alnylam Pharmaccuticals, Inc. March 15 , 2004 Name of Signer (Print or Type) Title of Signer (Print or Type) John Maraganore President and Chief Executive Officer

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)